Core Insights - Ascentage Pharma's novel drugs, lisaftoclax (APG-2575) and olverembatinib, have been included in the 2025 CSCO Guidelines, marking significant advancements in the treatment of hematological malignancies [1][9] Group 1: Lisaftoclax (APG-2575) - Lisaftoclax (APG-2575) is the first China-developed Bcl-2 inhibitor to receive a recommendation in the CSCO Guidelines for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [2][3] - The drug has shown a high overall response rate and a favorable tolerability profile, with a lower incidence of tumor-lysis syndrome compared to other Bcl-2 inhibitors [3] - Lisaftoclax (APG-2575) is currently undergoing two registrational Phase III studies to broaden its treatment applications [3] Group 2: Olverembatinib - Olverembatinib has received an upgraded Level I recommendation in the CSCO Guidelines for treating children with Ph+ acute lymphoblastic leukemia (ALL) who have the T315I BCR-ABL1 mutation [4][5] - The drug retains Level I recommendations for chronic myeloid leukemia (CML) treatment across various phases and mutations, emphasizing its role in addressing multiple BCR::ABL1 mutations [6][7] - Olverembatinib is recognized as a major breakthrough in pediatric hematology and is included in the China National Reimbursement Drug List, enhancing patient accessibility [8][12] Group 3: Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on developing therapies for hematological malignancies and has been listed on both the Hong Kong Stock Exchange and Nasdaq [10][12] - The company has a diverse pipeline of innovative drug candidates targeting key proteins involved in cancer treatment, including Bcl-2 and MDM2-p53 inhibitors [11] - Ascentage Pharma aims to strengthen its R&D capabilities and accelerate clinical development to meet unmet medical needs globally [15]
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines